Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vigil Neuroscience, Inc. - Common Stock (NQ: VIGL )

9.900 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 17, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 9.900
Bid (Size) 2.100 (3)
Ask (Size) 11.47 (1)
Prev. Close 9.900
Today's Range 9.900 - 9.900
52wk Range 2.180 - 16.77
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting
From Vigil Neuroscience, Inc.
Via Globe NewsWire
Catalyst Pharmaceuticals, Xylem And Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga

Performance

YTD
-20.16%
-20.16%
1 Month
-20.89%
-20.89%
3 Month
-19.51%
-19.51%
6 Month
+22.22%
+22.22%
1 Year
+27.09%
+27.09%

More News

Read More
Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Vigil Neuroscience, Inc.
Via Globe NewsWire
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
AMC Preferred Equity Units, Accolade And Some Other Big Stocks Moving Higher On Friday
Via Benzinga
Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team
From Vigil Neuroscience, Inc.
Via Globe NewsWire
Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP
From Vigil Neuroscience, Inc.
Via Globe NewsWire
Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022
From Vigil Neuroscience, Inc.
Via Globe NewsWire
Carvana, Crocs And Other Big Losers From Monday
Via Benzinga
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
Via Benzinga
Why TuanChe Shares Are Trading Lower By 76%? Here Are 48 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
Via Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Cano Health, Vacasa, Organogenesis, And Some Other Big Stocks Moving Lower On Thursday
Via Benzinga
Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via Globe NewsWire
Vigil Neuroscience to Present at Upcoming Investor Conferences
From Vigil Neuroscience, Inc.
Via Globe NewsWire
Vigil Neuroscience Touts Positive Healthy Volunteer Data From Lead Program In Rare Neurological Disease
Via Benzinga
Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP
From Vigil Neuroscience, Inc.
Via Globe NewsWire
Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP
From Vigil Neuroscience, Inc.
Via Globe NewsWire
Why Quoin Pharmaceuticals Shares Jumped By More Than 44%; Here Are 57 Biggest Movers From Yesterday
Via Benzinga
Marten Transport, Silvergate Capital And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.